Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.46 |
| ▸ | LIPE | Q05469 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5937862 | 1.00 | NR1H2 (0.51) | NR1H2DDB1CRBNLIPEGPR119 | |
| SCHEMBL16199623 | 1.00 | NR1H2 (0.51) | NR1H2DDB1CRBNLIPEGPR119 | |
| SCHEMBL15077724 | 0.90 | GPR119 (0.48) | NR1H2GPR119KDM4EMAPTTHRB | |
| SCHEMBL5938533 | 0.90 | GPR119 (0.48) | NR1H2GPR119KDM4EMAPTTHRB | |
| SCHEMBL26963296 | 0.90 | GPR119 (0.48) | NR1H2GPR119KDM4EMAPTTHRB | |
| SCHEMBL25048178 | 0.90 | GPR119 (0.48) | NR1H2GPR119KDM4EMAPTTHRB | |
| SCHEMBL5937898 | 0.90 | GPR119 (0.48) | NR1H2GPR119KDM4EMAPTTHRB | |
| SCHEMBL13727442 | 0.89 | NR1H2 (0.58) | NR1H2DDB1CRBNLIPEGPR119 | |
| SCHEMBL20566526 | 0.89 | NR1H2 (0.58) | NR1H2DDB1CRBNLIPEGPR119 | |
| SCHEMBL22270526 | 0.89 | NR1H2 (0.58) | NR1H2DDB1CRBNLIPEGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4291562-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116783202-A | Thienopyrrole compounds | 吉利德科学公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022173722-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-3312164-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3312164-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3122729-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9403801-B2 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150274704-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| WO-2015148867-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | NR1H2 301/4885DDB1 2574/4885CRBN 4503/4885 |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | NR1H2 1364/4885DDB1 1785/4885CRBN 4050/4885 |
| US-20150274704-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | NR1H2 976/4885DDB1 1408/4885CRBN 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.